ストックスクリーナーアプリを入手
2.00
5.82%
0.11
プレマーケット:
2.09
0.09
+4.50%
Io Biotech Inc (IOBT) 最新ニュース
IO Biotech, Inc.'s (NASDAQ:IOBT) largest shareholders are private equity firms who were rewarded as market cap surged US$16m last week - simplywall.st
Private equity firms are IO Biotech, Inc.'s (NASDAQ:IOBT) biggest owners and were rewarded after market cap rose by US$16m last week - Yahoo Finance
Why BrightSpire Capital Inc. stock attracts strong analyst attentionFree Investment Portfolio Suggestions - Newser
Why Chesapeake Utilities Corporation stock attracts strong analyst attentionSmart Money Signals - Newser
How IO Biotech Inc. stock performs during market volatilityTrade With Low Risk Exposure - Newser
What makes IO Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser
How OXBR stock performs during market volatilityGrowth Optimized Stock Radar - Newser
Why Semtech Corporation stock attracts strong analyst attentionFree Trading Strategy Suggestions - Newser
Does IO Biotech Inc (NASDAQ: IOBT) Still Need To Convince Analysts? - Stocksregister
What makes La Rosa Holdings Corp. stock price move sharplyFree Stock Market Beginners Guide - Newser
How The Shyft Group Inc. stock performs during market volatilityReal Trader Insights - Newser
How Douglas Dynamics Inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser
Why Medalist Diversified REIT Inc. stock attracts strong analyst attentionReal Chart Play - Newser
How Zillow Group Inc. stock performs during market volatilityTriple Return With Stability - Newser
Company stock price move sharplyExpert Trading Flow - Newser
Why IO Biotech Inc. stock attracts strong analyst attentionBreakout Momentum Alerts - Newser
ProKidney's Innovative CKD Treatment Sparks Biotech InterestNews and Statistics - IndexBox
FDA Transparency: A Catalyst for Market Efficiency and Regulatory Risk Mitigation in Biotech/Pharma - AInvest
Top 5 Synthetic Biology Public Companies (July 2025) - Securities.io
IO Biotech (NASDAQ:IOBT) Shares Up 1.4% – Here’s What Happened - Defense World
Melanoma Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Top 5 Lab-Grown Meat Stocks to Invest In (July 2025) - Securities.io
IO Biotech secures €12.5M EIB funding, issues 4.2M-share warrant | IOBT SEC FilingForm 8-K - Stock Titan
IO Biotech Amends CEO Service Agreement - TipRanks
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Down 35.0% in May - Defense World
IO Biotech Regains Nasdaq Compliance with Stock Price - MSN
Wall Street Zen Upgrades IO Biotech (NASDAQ:IOBT) to “Sell” - Defense World
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies | DelveInsight - The Globe and Mail
Metastatic Melanoma Pipeline Appears Robust With 20+ Key Pharma - openPR.com
IO Biotech reports annual meeting results By Investing.com - Investing.com Nigeria
IO Biotech reports annual meeting results - Investing.com India
IO Biotech Elects New Director at Annual Meeting - TipRanks
Citadel Advisors LLC Purchases Shares of 270,504 IO Biotech, Inc. (NASDAQ:IOBT) - Defense World
IO Biotech Regains Compliance With Nasdaq Listing Rules - marketscreener.com
io biotech regains nasdaq compliance after bid price recovery By Investing.com - Investing.com India
io biotech regains nasdaq compliance after bid price recovery - Investing.com
Director Heidi Hunter Acquires 15,000 Shares of IO Biotech Inc (IOBT) - GuruFocus
Stocks in play: Corus Entertainment - The Globe and Mail
Io biotech director Heidi Hunter purchases $20,884 in common stock By Investing.com - Investing.com South Africa
Io biotech director Heidi Hunter purchases $20,884 in common stock - Investing.com Australia
Top 10 Pharmaceutical Stocks For Healthcare Innovation (June 2025) - Securities.io
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
Pembina Pipeline Corporation Announces Redemption of Series 19 Preferred Shares - The Globe and Mail
3 Internet Software Stocks to Buy From a Prospering Industry - The Globe and Mail
Cancer Vaccines Market Sees Boost from UK's New Injection and Korea's Cell Conversion Research - openPR.com
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):